;Clinical TrialsFDA clinical trials in 2026: Technology enabled, patient centered, inspection readyRead moreFrom pilot to practice: FDA's evolving use of real-world evidenceRead moreLicensing implications of AI use in medical productsRead moreFDA BIMO inspection trends: Key takeaways and practical guidance for sponsorsRead moreAn overview of the new EU Biotech ActRead moreEU Biotech Act: Implications for clinical trial sponsorsRead moreData protection in clinical trials under the EU Biotech Act: A shift toward greater harmonizationRead moreFast-track authorization pathways for clinical trials: the European initiative and national implementationsRead moreUK clinical trials: Regulatory reform fuels new era of growth and global ambitionRead moreHarmonizing data protection practices under Germany's new standard contractual clauses for CTAsRead moreTrial diversity in the EU: Women and pregnant or lactating womenRead moreDecentralized clinical trials in France: Identifying barriers to progressRead moreCongress, FDA advance policies to phase out animal testingRead moreLDTs, IVDs, RUOs, reagents, collection kits, and analytical software: Where FDA is drawing the linesRead moreFDA signals long-awaited embrace of Bayesian methods in drug and biologic trialsRead morePrevious pageNext page
